|

Universal CD19 CAR-γδT Cell Injection Clinical Trials

1 actively recruiting trial

Also known as: QH103 Cell Injection

Pipeline

Phase 1: 1

Top Sponsors

  • Tongji Hospital1

Indications

  • Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD)1
  • Idiopathic Inflammatory Myopathies(IIM)1
  • Autoimmune Encephalitis (AE)1
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1
  • Myasthenia Gravis (MG)1

Other1 trial

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.